MetLife Investment Management’s Assembly Biosciences ASMB Stock Holding History

MetLife Investment Management’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,087	Closed	-$214K	–	2274
2020 Q3	$214K	Hold	1,087	–	–	﹤0.01%	1824
2020 Q2	$304K	Hold	1,087	–	–	﹤0.01%	1645
2020 Q1	$193K	Buy	1,087 +273	+34%	+$58.5K	﹤0.01%	1717
2019 Q4	$200K	Hold	814	–	–	﹤0.01%	1979
2019 Q3	$96K	Hold	814	–	–	﹤0.01%	2311
2019 Q2	$132K	Hold	814	–	–	﹤0.01%	2251
2019 Q1	$192K	Hold	814	–	–	﹤0.01%	2001
2018 Q4	$221K	Hold	814	–	–	﹤0.01%	1855
2018 Q3	$363K	Buy	814 +214	+36%	+$100K	﹤0.01%	1739
2018 Q2	$282K	Buy	+600	New	+$317K	﹤0.01%	1742
2018 Q1	–	Sell	-600	Closed	-$326K	–	2187
2017 Q4	$326K	Buy	+600	New	+$272K	﹤0.01%	1659

Other funds holding ASMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

MetLife Investment Management's ASMB Position: Q4 2020 in Review

MetLife Investment Management sold out of Assembly Biosciences (ASMB) in Q4 2020, closing a stake of 1,087 shares — an estimated $214K sold.

MetLife Investment Management first reported a position in ASMB in Q4 2017 and held it in 11 quarters. The position peaked at $363K in Q3 2018. 109 funds tracked by Wall St. Rank hold ASMB as of Q4 2020.

MetLife Investment Management reported no remaining Assembly Biosciences position as of Q4 2020 after selling out during the quarter.
MetLife Investment Management sold 1,087 Assembly Biosciences shares in Q4 2020, an estimated $214K.
MetLife Investment Management first reported a position in Assembly Biosciences in Q4 2017 and held it in 11 quarters.
MetLife Investment Management's Assembly Biosciences position peaked at $363K in Q3 2018.
109 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.